Gilead (GILD) nears up to USD 2bln deal for autoimmune biotech Ouro Medicines, according to FT

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

French Energy Minister says general study is being launched to look at possibility fo augment french refining capacity; focus will be mainly on fuel and diesel

Apple (AAPL) to announce ad programme for the maps app as soon as this month in services push, according to Bloomberg

Gilead (GILD) nears up to USD 2bln deal for autoimmune biotech Ouro Medicines, according to FT

Washington reportedly sets April 9th as the date to end the war on Iran, according to an Israeli Official to Yedioth Ahronoth

EUROPEAN CLOSES: Euro Stoxx 50 +1.42% at 5,579, Dax 40 +0.96% at 22,595, FTSE 100 -0.15% at 9,903, CAC 40 +0.79% at 7,726, FTSE MIB +0.91% at 43,230, IBEX 35 +1.04% at 16,888, PSI +0.25% at 8,779, SMI +0.61% at 12,411, AEX +0.53% at 967

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Context

Gilead's potential acquisition of Ouro Medicines for up to USD 2 billion marks a significant move in the biotech space, particularly in the autoimmune sector. This deal could bolster Gilead's pipeline and may indicate a strategic shift towards expanding its therapeutic offerings, which is crucial given the competitive landscape. Market sentiment may react favorably if investors view the acquisition as accretive and synergistic with Gilead's existing portfolio.

Related headlines

The feed had this first.

Use the Platform